Eam Investors, LLC Avenue Therapeutics, Inc. Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$2.95 - $11.04 $212,004 - $793,400	-71,866 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$9.37 - $12.06 $228,524 - $294,131	-24,389 Reduced 25.34%	71,866 $778,000
Q1 2020 May 13, 2020	BUY	$6.44 - $11.32 $24,742 - $43,491	3,842 Added 4.16%	96,255 $861,000
Q4 2019 Feb 11, 2020	SELL	$5.26 - $9.6 $104,268 - $190,300	-19,823 Reduced 17.66%	92,413 $887,000
Q3 2019 Nov 13, 2019	BUY	$5.58 - $6.3 $206,086 - $232,677	36,933 Added 49.05%	112,236 $669,000

Q2 2019 Aug 14, 2019	SELL	$4.33 - $6.54 $72,150 - $108,976	-16,663 Reduced 18.12%	75,303 $474,000
Q1 2019 May 13, 2019	BUY	$4.75 - $6.59 $436,838 - $606,055	91,966 New	91,966 $437,000

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $13.8M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.